Phuong-Thao Tran | Medicinal Chemistry | Best Researcher Award

Published on by Academic Achievements

Best Researcher Award

Phuong-Thao Tran
Hanoi University of Pharmacy, Vietnam

Phuong-Thao Tran
Affiliation Hanoi University of Pharmacy
Country Vietnam
Scopus ID 55908125500
Documents 51
Citations 660
h-index 17
Subject Area Medicinal Chemistry, neurodegenerative disorders, Alzheimer’s disease
Event International Academic Achievements & Awards
ORCID 0000-0003-4855-2544

Phuong-Thao Tran is a researcher at Hanoi University of Pharmacy, Vietnam, whose work centers on medicinal chemistry and the discovery of compounds relevant to neurodegenerative disorders, particularly Alzheimer’s disease.[1] This article presents her profile in the context of the Best Researcher Award at the International Academic Achievements & Awards event.

Abstract

Phuong-Thao Tran is a medicinal chemistry researcher affiliated with Hanoi University of Pharmacy. Her publications address the design and evaluation of enzyme inhibitors for Alzheimer’s disease, including inhibitors of human glutaminyl cyclase and acetylcholinesterase, together with related studies in cancer biology.[2] With 51 indexed documents and 660 citations, her record reflects sustained and recognized scholarly activity in drug discovery.

Keywords

Medicinal chemistry, Alzheimer’s disease, neurodegenerative disorders, glutaminyl cyclase inhibitors, acetylcholinesterase, structure–activity relationship, computational drug design.

Introduction

Neurodegenerative disorders, especially Alzheimer’s disease, remain among the most difficult challenges in modern therapeutics. Medicinal chemists contribute by identifying molecular targets and designing compounds that can modulate them. Phuong-Thao Tran works in this field at Hanoi University of Pharmacy, combining synthetic chemistry, structure–activity analysis and computational approaches.[1] Her work has appeared in journals such as the Journal of Medicinal Chemistry, Bioorganic & Medicinal Chemistry, ACS Omega and Cancers.

Research Profile

According to Scopus, the researcher’s author record (ID 55908125500) includes 51 documents, 660 citations and an h-index of 17.[1] Her principal subject areas are medicinal chemistry and neurodegenerative disorders, with a particular emphasis on Alzheimer’s disease. Her ORCID record provides a further public listing of her scholarly outputs.[5]

Research Contributions

Her contributions can be grouped into several themes:

  • Glutaminyl cyclase inhibitors. Rational design of potent human glutaminyl cyclase inhibitors as candidate anti-Alzheimer’s agents, together with structure–activity studies of inhibitors built on an imidazolyl propyl thiourea template.[2][3]
  • Acetylcholinesterase studies. Computational and experimental work on predicting ligand affinity and identifying possible inhibitors through umbrella sampling and machine learning.[4]
  • Cancer biology. A review of the emerging role of circulating tumor cells in gastric cancer, indicating a broader biomedical scope.

Publications

Selected highly cited publications, with citation counts as listed in the supplied profile data, include:

  • “Discovery of potent human glutaminyl cyclase inhibitors as anti-Alzheimer’s agents based on rational design,” Journal of Medicinal Chemistry 60(6), 2573–2590 (2017); 64 citations.[2]
  • “Emerging role of circulating tumor cells in gastric cancer,” Cancers 12(3), 695 (2020); 60 citations.
  • “Structure Activity Relationship of Human Glutaminyl Cyclase Inhibitors Having an N-(5-Methyl-1H-imidazol-1-yl)propyl Thiourea Template,” Bioorganic & Medicinal Chemistry (2013); 45 citations.[3]
  • “Prediction of AChE-ligand affinity using the umbrella sampling simulation,” Journal of Molecular Graphics and Modelling 93, 107441 (2019); 43 citations.
  • “Identifying possible AChE inhibitors from drug-like molecules via machine learning and experimental studies,” ACS Omega 7(24), 20673 (2022); 35 citations.[4]

Research Impact

The researcher’s impact is reflected in citation metrics and in the longevity of her work. Publications from 2013 to 2022 continue to attract citations, and the most cited paper, on glutaminyl cyclase inhibitors, has 64 citations.[1] An h-index of 17 indicates that at least 17 of her documents have each been cited at least 17 times. Her combination of experimental and computational methods also supports the reuse of her findings in later drug-design studies.

Award Suitability

The Best Researcher Award at the International Academic Achievements & Awards event recognizes researchers with significant scholarly contributions.[5] Phuong-Thao Tran’s profile aligns with such criteria through:

  • A focused research agenda in medicinal chemistry and Alzheimer’s disease therapeutics.
  • A publication record in peer-reviewed international journals.
  • Citation indicators of 660 citations and an h-index of 17.
  • Methodological breadth spanning synthesis, structure–activity analysis and computational modelling.

Conclusion

Phuong-Thao Tran of Hanoi University of Pharmacy has built a research record centered on the discovery of enzyme inhibitors relevant to Alzheimer’s disease. Her publications, citation metrics and methodological range support her nomination for the Best Researcher Award at the International Academic Achievements & Awards event.[1]

References

  1. Elsevier. (n.d.). Scopus author details: Phuong-Thao Tran, Author ID 55908125500. Scopus.
    https://www.scopus.com/authid/detail.uri?authorId=55908125500
  2. Hoang, V. H., Tran, P. T., Cui, M., Ngo, V. T. H., Ann, J., Park, J., Lee, J., Choi, K., Cho, H., et al. (2017). Discovery of potent human glutaminyl cyclase inhibitors as anti-Alzheimer’s agents based on rational design. Journal of Medicinal Chemistry, 60(6), 2573–2590.
    https://pubmed.ncbi.nlm.nih.gov/28234463/
  3. Tran, P. T., Hoang, V. H., Thorat, S. A., Kim, S. E., Ann, J., Chang, Y. J., Nam, D. W., et al. (2013). Structure activity relationship of human glutaminyl cyclase inhibitors having an N-(5-methyl-1H-imidazol-1-yl)propyl thiourea template. Bioorganic & Medicinal Chemistry.
    https://doi.org/10.1016/j.bmc.2013.08.027
  4. Nguyen, T. H., Tran, P. T., Pham, N. Q. A., Hoang, V. H., Hiep, D. M., & Ngo, S. T. (2022). Identifying possible AChE inhibitors from drug-like molecules via machine learning and experimental studies. ACS Omega, 7(24), 20673.
    https://doi.org/10.1021/acsomega.2c01341
  5. ORCID. (n.d.). Phuong-Thao Tran (ORCID iD 0000-0003-4855-2544). ORCID.
    https://orcid.org/0000-0003-4855-2544

Neeraj Thakur | Pharmacology | Innovative Research Award

Published on by Academic Achievements

Innovative Research Award

Neeraj Thakur
Affiliation University of Oklahoma Health Campus
Country United States
Scopus ID 56645996700
Documents 37
Citations 1,149
h-index 20
Subject Area Pharmacology, Toxicology and Pharmaceutical Science
Event International Academic Achievements & Awards
ORCID 0000-0003-1758-0737

Neeraj Thakur
University of Oklahoma Health Campus, United States

The Innovative Research Award recognizes sustained scholarly excellence, impactful scientific contributions, and innovation in biomedical and pharmaceutical sciences. Neeraj Thakur has established an active research profile focused on advanced drug delivery systems, nanomedicine, pharmaceutical formulations, biomaterials, and translational therapeutic technologies. His published work demonstrates interdisciplinary collaboration across pharmaceutical science, toxicology, and biomedical engineering while contributing to improved therapeutic delivery strategies for dermatological and ocular applications.[1]

Abstract

Neeraj Thakur’s research integrates pharmaceutical sciences, nanotechnology, biomaterials, and targeted therapeutic delivery to address challenges associated with drug stability, controlled release, tissue targeting, and improved clinical efficacy. His work encompasses hybrid micellar systems, ocular nanoformulations, RNA interference technologies, and advanced pharmaceutical carriers designed to improve patient outcomes through innovative formulation strategies.[2]

Keywords

Drug Delivery Systems, Nanomedicine, Hybrid Micelles, RNA Interference, Corneal Therapeutics, Pharmaceutical Sciences, Targeted Drug Delivery

Introduction

Modern pharmaceutical research increasingly focuses on precision drug delivery, sustained therapeutic release, and biomaterial-enabled treatment strategies. Neeraj Thakur’s research aligns with these objectives through the development of multifunctional nanocarriers and advanced pharmaceutical formulations capable of enhancing therapeutic performance while minimizing adverse effects. His publications demonstrate an interdisciplinary approach combining pharmaceutical sciences with materials engineering and translational medicine.[3]

Research Profile

  • Scopus Author ID: 56645996700
  • 37 indexed scholarly publications.
  • 1,149 citations reflecting broad scientific visibility.
  • h-index of 20 demonstrating consistent research influence.
  • Research spans pharmacology, toxicology, pharmaceutical sciences, nanomedicine and biomaterials.

Research Contributions

The research contributions of Neeraj Thakur include the design of crosslinked hybrid micellar systems for cutaneous drug delivery, sustained nanoformulations for corneal wound healing, and RNA interference applications in viral diagnostics and therapeutics. These investigations emphasize formulation optimization, targeted delivery, therapeutic efficiency, and translational biomedical applications while supporting the broader advancement of pharmaceutical technology.[4]

Publications

  • Crosslinked hybrid micellar platform for targeted cutaneous drug delivery
    Colloids and Surfaces B: Biointerfaces (2026). DOI: 10.1016/j.colsurfb.2026.115998
  • Crosslinked Hybrid Micellar Platform for Targeted Cutaneous Drug Delivery
    Preprint (2026). DOI: 10.2139/ssrn.6250431
  • A multimodal approach to smart and sustained drug delivery for corneal wound management: the GelPol nanoformulation
    Nanomedicine (2025). DOI: 10.1080/17435889.2025.2550236
  • RNAi in viral control and diagnostics
    Book Chapter (2025). DOI: 10.1088/978-0-7503-4987-1ch12

Research Impact

The documented citation profile, publication record, and interdisciplinary research portfolio indicate sustained academic influence within pharmaceutical sciences. Contributions toward targeted drug delivery technologies and nanomedicine support ongoing developments in precision therapeutics, controlled release formulations, and biomedical innovation. The citation metrics further demonstrate recognition by the international research community.[1]

Award Suitability

Based on the available scholarly metrics, publication output, interdisciplinary research contributions, and demonstrated impact within pharmaceutical sciences, Neeraj Thakur represents a suitable candidate for recognition through the Innovative Research Award. His research portfolio reflects innovation in drug delivery technologies, sustained scientific productivity, and contributions supporting future translational healthcare solutions.[2]

Conclusion

Neeraj Thakur has established a notable research profile characterized by innovation in pharmaceutical formulation science, targeted therapeutic delivery, nanotechnology, and biomaterial-based treatment strategies. Supported by strong bibliometric indicators and peer-reviewed scholarly publications, his work contributes to the continued advancement of pharmaceutical sciences and biomedical research while reflecting the qualities recognized by the Innovative Research Award.[4]

References

  1. Elsevier. (n.d.). Scopus author details: Neeraj Thakur, Author ID 56645996700. Scopus.
    https://www.scopus.com/authid/detail.uri?authorId=56645996700
  2. Thakur, N. (2026). Crosslinked hybrid micellar platform for targeted cutaneous drug delivery. Colloids and Surfaces B: Biointerfaces.
    https://doi.org/10.1016/j.colsurfb.2026.115998
  3. Thakur, N. (2026). Crosslinked Hybrid Micellar Platform for Targeted Cutaneous Drug Delivery. SSRN Preprint. https://doi.org/10.2139/ssrn.6250431
  4. Thakur, N. (2025). A multimodal approach to smart and sustained drug delivery for corneal wound management: the GelPol nanoformulation. Nanomedicine. https://doi.org/10.1080/17435889.2025.2550236
  5. Thakur, N. (2025). RNAi in viral control and diagnostics. Viral Diseases: History and New Developments in Diagnostics and Therapeutics.
    https://doi.org/10.1088/978-0-7503-4987-1ch12

Jana Wattar | Pharmacology | Women Researcher Award

Published on by Academic Achievements

Women Researcher Award

Jana K. Al Wattar
Lebanese International University,  Lebanon
Jana K. Al Wattar
Affiliation Lebanese International University
Country Lebanon
Scopus ID 56999102300
Documents 9
Citations 172
h-index 5
Subject Area Pharmacology, Toxicology and Pharmaceutical Science
Event International Academic Achievements & Awards

Jana K. Al Wattar is a Lebanese pharmaceutical scientist, academic researcher, and Assistant Professor specializing in pharmaceutical sciences, nanotechnology-based drug delivery systems, and translational nanomedicine. Her research primarily focuses on smart lipid-based nanocarriers for cancer therapeutics and neurodegenerative disorders, with emphasis on enhancing therapeutic efficacy, improving drug bioavailability, and overcoming multidrug resistance mechanisms.[1]

Over more than a decade of academic and professional engagement, Dr. Al Wattar has contributed extensively to pharmaceutical education, interdisciplinary nanomedicine research, and international scientific collaboration. Her work integrates pharmaceutical technology, nanotechnology, biotechnology, and biomedical innovation through collaborative partnerships across Lebanon, the Gulf region, and international academic institutions.[2]

Abstract

Jana K. Al Wattar has established a distinguished research profile in pharmaceutical sciences with specialization in nanotechnology-based therapeutic delivery systems for oncology and neurological disorders. Her scientific contributions encompass the formulation, optimization, and characterization of smart nanocarriers, including nanovesicles, nanosponge systems, liposomal nanohybrids, electrohydrodynamic nanofibers, and stimuli-responsive drug delivery platforms.[3]

Her work demonstrates interdisciplinary integration of pharmaceutical technology, nanomedicine, biomaterials, and translational therapeutics. In addition to publishing in internationally recognized journals, she has actively contributed to scientific conferences, secured competitive research grants, supervised collaborative projects, and established institutional research partnerships across the Middle East and beyond.[4]

Keywords

Nanomedicine; Pharmaceutical Technology; Drug Delivery Systems; Lipid Nanocarriers; Cancer Therapeutics; Neurodegenerative Disorders; Smart Nanovesicles; Nanotechnology; Biomaterials; Pharmaceutical Biotechnology; Liposomal Systems; Targeted Drug Delivery; Tissue Engineering; Translational Medicine; Pharmaceutical Sciences

Introduction

Advances in nanotechnology and pharmaceutical sciences have transformed the development of targeted therapeutic systems for complex diseases including cancer and neurodegenerative disorders. Researchers in pharmaceutical nanotechnology contribute significantly to improving therapeutic outcomes through innovative drug delivery systems that enhance bioavailability, stability, specificity, and patient safety. Dr. Jana K. Al Wattar has contributed to this evolving field through sustained academic research focused on nanocarrier engineering, smart drug delivery systems, and translational pharmaceutical applications.[5]

Her research vision aims to establish a translational nanomedicine platform in the Levant region that addresses unmet therapeutic challenges associated with drug resistance, poor bioavailability, and targeted treatment delivery. Her academic and scientific activities demonstrate commitment to regional research development, scientific leadership, and interdisciplinary collaboration.

Research Profile

Dr. Al Wattar currently serves as a Full-time Assistant Professor in the Department of Pharmaceutical Sciences at Lebanese International University in Beirut, Lebanon. Her teaching portfolio includes pharmaceutics, dosage forms, pharmaceutical calculations, physical pharmacy, compounding laboratories, biotechnology laboratories, and pharmacy practice experience courses.

Her academic experience spans more than twelve years in higher education, during which she has contributed to undergraduate and postgraduate mentorship, pharmaceutical curriculum development, and scientific supervision. Prior to her current appointment, she served as Lecturer Assistant at Beirut Arab University and Instructor at Lebanese International University.

Her doctoral studies in Pharmaceutical Technology and Industrial Pharmacy at Beirut Arab University focused on innovative nanotechnology-based formulations and advanced pharmaceutical delivery systems. Her academic trajectory has consistently emphasized pharmaceutical innovation and translational therapeutic applications.

Research Contributions

Dr. Al Wattar has contributed substantially to nanomedicine research through development and optimization of advanced drug delivery systems. Her investigations focus on enhancing therapeutic efficacy while minimizing toxicity through rational nanocarrier design and smart pharmaceutical engineering strategies.

  • Development of lipid-based nanocarriers for targeted cancer therapeutics.
  • Optimization of nanovesicle systems for neurological and neuroinflammatory disorders.
  • Investigation of smart stimuli-responsive liposomal nanohybrid systems for theranostic applications.
  • Research on electrohydrodynamic atomization for fast-dissolving drug delivery systems.
  • Studies involving thymoquinone-loaded nanosystems for oxidative stress modulation and anticancer activity.
  • Collaborative interdisciplinary projects involving biomaterials, tissue engineering, and pharmaceutical biotechnology.

Her collaborative network extends across leading institutions in Lebanon, the United Arab Emirates, Jordan, and Egypt, demonstrating active international scientific engagement in pharmaceutical nanotechnology and translational biomedical sciences.

Publications

Jana K. Al Wattar has authored and co-authored numerous peer-reviewed publications in pharmaceutical sciences, nanomedicine, and drug delivery research. Her scholarly work focuses on lipid nanovesicles, smart nanocarriers, cancer therapeutics, neurodegenerative disorders, and pharmaceutical biotechnology, contributing to advancements in targeted drug delivery systems and translational pharmaceutical innovation.

Research Impact

Dr. Al Wattar’s research contributes to advancing pharmaceutical nanotechnology and translational medicine in the Middle East region. Her work on smart nanocarrier systems addresses critical biomedical challenges related to targeted therapy, controlled drug release, and therapeutic optimization.

Her scholarly contributions have been recognized through multiple academic distinctions, including research grants, best oral presentation awards, poster awards, and competitive doctoral scholarships. These recognitions reflect sustained engagement in innovative pharmaceutical research and academic leadership.

Beyond publications, her impact is evident in scientific mentorship, supervision of institutional collaborations, and active involvement in regional capacity-building initiatives related to pharmaceutical sciences and biomedical innovation.

Award Suitability

Dr. Jana K. Al Wattar demonstrates qualifications aligned with the criteria of an Outstanding Researcher Award through her interdisciplinary scientific contributions, international collaborations, research leadership, and commitment to pharmaceutical innovation.

  • Extensive expertise in nanotechnology-based drug delivery systems.
  • Strong publication profile in pharmaceutical and nanomedicine journals.
  • Leadership in regional and international collaborative research initiatives.
  • Successful acquisition of competitive research grants and academic awards.
  • Long-standing commitment to pharmaceutical education, mentorship, and scientific capacity building.

Conclusion

Dr. Jana K. Al Wattar represents a significant emerging voice in pharmaceutical nanotechnology and translational drug delivery research. Her academic profile combines innovative scientific investigation, interdisciplinary collaboration, educational leadership, and regional research development. Through sustained contributions to nanomedicine, targeted therapeutics, and pharmaceutical sciences, she continues to strengthen scientific advancement within the Levant region and the broader international biomedical research community.

References

  1. Lebanese International University. (2026). Faculty profile of Dr. Jana K. Al Wattar.
  2. Beirut Arab University. (2025). Academic and research activities in pharmaceutical sciences.
  3. Alwattar, J.K., et al. (2021). Smart stimuli-responsive liposomal nanohybrid systems: A critical review of theranostic behavior in cancer. Pharmaceutics.
  4. AAU Health & Biomedical Symposium. (2024). Conference awards and scientific participation records.
  5. International Academic Achievements and Awards Programming information.                          International Academic Achievements & Awards